Published by GlobalData
on Dec 31, 2012
, 161 pages
PDF format - Delivered by Email within 1 business day
GlobalData has released its new Country report, "PharmaPoint: Prostate Cancer - Germany Drug Forecast and Market Analysis to 2022". The recent approvals of second-line metastatic castration-resistant prostate cancer (mCRPC) therapies like J&J's Zytiga (abiraterone acetate) and Medivation/Astellas' Xtandi (enzalutamide) will drive strong market growth over the next decade. These safe and orally administered treatments will provide safety and convenience benefits over the current standard of care, chemotherapy with docetaxel, while prolonging the overall survival of patients with mCRPC. The December 12, 2012 FDA approval of Zytiga for the added indication of chemotherapy-naive mCRPC marks the onset of a new treatment paradigm for the disease, in which chemotherapy is relegated to second-line therapy and beyond. For patients with earlier-stage prostate cancer, androgen deprivation therapy with LHRH agonists and first-generation antiandrogens remains the standard of care for suppressing testosterone levels and temporarily controlling the disease.
In Germany, PSA screening and DREs are the most common diagnostic techniques used to detect prostate cancer (EAU, 2012). Routine PSA screening is widespread, but is used less frequently than in the US. Although the USPSTF has recommended against routine PSA screening to detect prostate cancer, German physicians do not anticipate making any changes in their routine screening patterns. Nor do they expect the screening patterns of referring physicians to change in the near future. To confirm the diagnosis of prostate cancer following an elevated PSA level or other symptoms, physicians use core needle biopsies or TRUS. Any metastases are detected by bone scans or CT scans.
- Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Germany including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Germany from 2012 to 2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the Germany Prostate cancer market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Prostate cancer
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Prostate cancer drug performance in Germany
- Obtain sales forecast from 2012-2022 in Germany